Inventor · disambiguated record
Brion W. Murray
Also filed as: MURRAY BRION W · MURRAY BRION WILLIAM
10 granted patents·6 pending applications·69 citations·filing 1997–2023
87Inventor score
Files withTURNING POINT THERAPEUTICS INC5SIGNAL PHARM INC3SIGNAL PHARMACEUTICALS3SIGNAL PHARM LLC2PFIZER1
Top patents by PatentIndex Score
16 records- 0183US6576437B2Stimulus-inducible protein kinase complex and methods of use thereforSIGNAL PHARM INC·Filed 2001·Granted Jun 10, 2003·13 cites·10 claims
- 0282US7119114B1Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related theretoSIGNAL PHARM LLC·Filed 2000·Granted Oct 10, 2006·16 cites·19 claims
- 0374US7285654B2Stimulus-inducible protein kinase complex and methods of use thereforSIGNAL PHARMACEUTICALS·Filed 2003·Granted Oct 23, 2007·4 cites·18 claims
- 0472US6258579B1Stimulus-inducible protein kinase complex and methods of use thereforSIGNAL PHARM INC·Filed 1997·Granted Jul 10, 2001·28 cites·4 claims
- 0569US2024033266A1Combination therapy involving diaryl macrocyclic compoundsTURNING POINT THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0667US2023398119A1Combination therapy involving diaryl macrocyclic compoundsTURNING POINT THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0763US11654145B2Combination therapy involving diaryl macrocyclic compoundsTURNING POINT THERAPEUTICS INC·Filed 2020·Granted May 23, 2023·0 cites·30 claims
- 0862US11666574B2Combination therapy involving diaryl macrocyclic compoundsTURNING POINT THERAPEUTICS INC·Filed 2020·Granted Jun 6, 2023·0 cites·17 claims
- 0961US7759476B2Double-stranded RNAS directed to IKK-2SIGNAL PHARMACEUTICALS·Filed 2007·Granted Jul 20, 2010·0 cites·11 claims
- 1055US2025262216A1Therapeutic uses of macrocyclic compoundsTURNING POINT THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1153US7335676B2Methods for treating inflammatory conditions or inhibiting JNKSIGNAL PHARM LLC·Filed 2003·Granted Feb 26, 2008·0 cites·6 claims
- 1250US7358056B1Methods for modulating signal transduction mediated by TGF-β and related proteinsSIGNAL PHARMACEUTICALS·Filed 1999·Granted Apr 15, 2008·8 cites·18 claims
- 1349US9205078B2N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemiaPFIZER·Filed 2012·Granted Dec 8, 2015·0 cites·7 claims
- 1447US2003119072A1Methods for modulating signal transduction mediated by TGF-beta related proteinsSIGNAL PHARM INC·Filed 2002·Application pending·0 cites
- 1546US2004072888A1Methods for treating inflammatory conditions or inhibiting JNKFiled 2003·Application pending·0 cites
- 1639US2004009568A1Catalytic domains of the human hepatocyte growth factor receptor tyrosine kinase, and materials and methods for identification of inhibitors thereofFiled 2002·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →